NZ594605A - Pharmaceutical compositions comprising anti miRNA antisense oligonucleotides - Google Patents
Pharmaceutical compositions comprising anti miRNA antisense oligonucleotidesInfo
- Publication number
- NZ594605A NZ594605A NZ594605A NZ59460507A NZ594605A NZ 594605 A NZ594605 A NZ 594605A NZ 594605 A NZ594605 A NZ 594605A NZ 59460507 A NZ59460507 A NZ 59460507A NZ 594605 A NZ594605 A NZ 594605A
- Authority
- NZ
- New Zealand
- Prior art keywords
- sequence
- units
- stranded oligonucleotide
- pharmaceutical compositions
- antisense oligonucleotides
- Prior art date
Links
- 108091070501 miRNA Proteins 0.000 title abstract 3
- 239000002679 microRNA Substances 0.000 title abstract 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title 1
- 239000000074 antisense oligonucleotide Substances 0.000 title 1
- 238000012230 antisense oligonucleotides Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 4
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed is a single-stranded oligonucleotide 8 to 24 nucleotides in length capable of reducing an effective amount of a miRNA in vitro or in a non-human cell or non-human organism, wherein said single stranded oligonucleotide comprises: (i) a sequence that is complementary to a sequence of said miRNA; (ii) a sequence comprising not more than 4 consecutive 2'-deoxyribose nucleoside (DNA) units; (iii) a sequence comprising more than 4 consecutive Locked Nucleic Acid (LNA) units; (iv) at least 30% of constituent nucleotides as LNA units; and (v) at least one internucleoside linkage group comprising a phosphorothioate, subject to the proviso that the single-stranded oligonucleotide does not comprise a core DNA sequence of 3'-ctcaca-5' from positions two to seven or from positions three to eight thereof counting from the 3' end of said oligonucleotide.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78899506P | 2006-04-03 | 2006-04-03 | |
| DKPA200600478 | 2006-04-03 | ||
| NZ571569A NZ571569A (en) | 2006-04-03 | 2007-03-30 | Pharmaceutical compositions comprising anti miRNA antisense oligonucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ594605A true NZ594605A (en) | 2013-03-28 |
Family
ID=36746645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ594605A NZ594605A (en) | 2006-04-03 | 2007-03-30 | Pharmaceutical compositions comprising anti miRNA antisense oligonucleotides |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN101437942A (en) |
| NZ (1) | NZ594605A (en) |
| ZA (1) | ZA200808420B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102311956B (en) * | 2011-09-20 | 2012-11-21 | 浙江大学 | Specific base modification antisense nucleotide chain and application thereof |
| CN105087477A (en) * | 2015-05-21 | 2015-11-25 | 王松灵 | Application of mesenchymal stem cell modified by miR-21 antisense nucleotide |
| JP2018517704A (en) * | 2015-06-05 | 2018-07-05 | ミラゲン セラピューティクス， インコーポレイテッド | MiR-155 inhibitor for treating amyotrophic lateral sclerosis (ALS) |
| JP6721252B2 (en) * | 2015-06-05 | 2020-07-08 | ミラゲン セラピューティクス， インコーポレイテッド | MiR-155 inhibitors for treating cutaneous T-cell lymphoma (CTCL) |
| WO2017053622A1 (en) * | 2015-09-22 | 2017-03-30 | MiRagen Therapeutics, Inc. | MiR-19 MODULATORS AND USES THEREOF |
| WO2017132945A1 (en) * | 2016-02-04 | 2017-08-10 | 中国科学技术大学 | Design and application of mirancer molecule |
| EP3841220A1 (en) * | 2018-08-23 | 2021-06-30 | Roche Innovation Center Copenhagen A/S | Microrna-134 biomarker |
| CN115337322B (en) * | 2021-05-13 | 2024-04-19 | 南京大学 | Application of RNA in preparation of products for treating pulmonary fibrosis related diseases |
-
2007
- 2007-03-30 NZ NZ594605A patent/NZ594605A/en not_active IP Right Cessation
- 2007-03-30 CN CNA2007800158808A patent/CN101437942A/en active Pending
-
2008
- 2008-10-02 ZA ZA200808420A patent/ZA200808420B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200808420B (en) | 2009-08-26 |
| CN101437942A (en) | 2009-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ594605A (en) | Pharmaceutical compositions comprising anti miRNA antisense oligonucleotides | |
| HRP20210612T1 (en) | Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna | |
| SG170780A1 (en) | Compositions and methods for inhibiting expression of eg5 gene | |
| WO2006032041A3 (en) | Compositions and methods for inhibiting expression of anti-apoptotic genes | |
| WO2007056326A3 (en) | Compositions and methods for inhibiting expression of nav1.8 gene | |
| JP2009524419A5 (en) | ||
| JP2015523853A5 (en) | ||
| WO2007051045A3 (en) | Compositions and methods for inhibiting expression of huntingtin gene | |
| EA201100812A1 (en) | PHARMACEUTICAL COMPOSITION | |
| EA200870402A1 (en) | PHARMACEUTICAL COMPOSITION | |
| JP2015519057A5 (en) | ||
| NZ593618A (en) | Gnaq targeted dsrna compositions and methods for inhibiting expression | |
| WO2008116860A3 (en) | Dsrna compositions and methods for treating hpv infections | |
| WO2007134161A3 (en) | Compositions and methods for inhibiting expression of the pcsk9 gene | |
| EP2322617A3 (en) | Short interfering ribonucleic acid (siRNA) for oral administration | |
| JP2014527401A5 (en) | ||
| JP2009532392A5 (en) | ||
| JP2015523855A5 (en) | ||
| WO2008036933A3 (en) | Compositions and methods for inhibiting expression of the hamp gene | |
| WO2008008719A3 (en) | Compositions and methods for inhibiting expression of the myc gene | |
| WO2007127919A3 (en) | Compositions and methods for inhibiting expression of a gene from the jc virus | |
| JP2007530431A5 (en) | ||
| WO2007137220A3 (en) | Compositions and methods for inhibiting expression of ikk-b gene | |
| WO2008109361B1 (en) | Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof | |
| WO2013013165A2 (en) | Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 MAR 2014 BY FB RICE Effective date: 20130716 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 MAR 2017 BY COMPUTER PACKAGES INC Effective date: 20140328 |
|
| ERR | Error or correction |
Free format text: THE OWNER HAS BEEN CORRECTED TO 3026191, SANTARIS PHARMA A/S, KOGLE ALLE 6, DK-2970 HORSHOLM, DK Effective date: 20150619 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2018 BY THOMSON REUTERS Effective date: 20170221 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2019 BY THOMSON REUTERS Effective date: 20180217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2020 BY THOMSON REUTERS Effective date: 20190216 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2021 BY THOMSON REUTERS Effective date: 20200205 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2022 BY THOMSON REUTERS Effective date: 20210206 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2023 BY THOMSON REUTERS Effective date: 20220302 |
|
| LAPS | Patent lapsed |